Advaxis, Inc. (ADXS)

Teaching the Immune System to Fight Cancer™

Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, Listeria monocytogenes (Lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.

Confronting a Global Issue

The World Health Organization estimates that 2.3 million woman are at risk for HPV-associated cervical cancer globally. Developed with cutting edge technology, we are currently investigating ADXS-HPV for the potential to lower that number.
Learn More

Advaxis Platform Technology

Advaxis is pioneering a patented platform technology using bio-engineered bacteria to secrete protein(s) being investigated to redirect the body's immune response to HPV-associated cancer. Much like a Trojan Horse... but on a smaller scale.
Learn More